1. Introduction {#s0005}
===============

*Streptococcus mutans* (*S. mutans*) is the main cariogenic bacteria causing dental caries ([@b0110], [@b0145]). The key component of *S. mutans* pathogenesis is; its ability to produce large quantities of glucans and acid that exceeding the salivary buffering capacities. *S. mutans* able to strongly bind to teeth and can survive in an acidic environment ([@b0110]).

Zinc is used as an antimicrobial, it has been added to mouth rinses and toothpaste to control dental plaque, inhibit calculus formation and reduce halitosis ([@b0100]). For many years zinc was incorporated into many dental materials due to the ability of zinc ion to inhibit the growth of cariogenic bacteria ([@b0035]). It is substantive in dental plaque and saliva, and its higher concentration can persist for many hours after delivery from oral health products ([@b0100]). It is considered a bacteriostatic agent rather than bactericidal, where its effect is reversed when cells are washed ([@b0130]).

Sufficient evidence is available in the literature to indicate the inhibitory effect of zinc against oral bacteria ([@b0130]). Zinc ion has multiple inhibitory effects on the intact bacterial cells activities such as glycolysis, glucosyltransferase production and polysaccharide synthesis, transmembrane proton translocation and acid tolerance ([@b0130]). It can enhance proton permeabilities of bacterial cells membranes, ([@b0130]) reduce Adenosine Triphosphate (ATP) synthesis in glycolyzing cells and diminish F-Type Adenosine Triphosphate Synthases (F-ATPase) activity due to its ability to inhibit of the glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenases and pyruvate kinase as well as the phosphoenolpyruvate ([@b0080]).

A vast number of published studies have used zinc oxide nanoparticles (ZnO-NPs) as an antibacterial agent ([@b0160]). ZnO-NPs is a bio-safe material, non-toxic to human cells ([@b0160]). Zinc in nanoparticles form is more toxic to bacteria than their micron equivalents ([@b0095]). The antimicrobial activity of ZnO-NPs may be due to the possible interaction between the nanoparticles and bacteria. ZnO-NPs can disturb the bacterial growth either by interacting with the bacterial surface or entering inside the bacterial cells. This leading to disrupt bacterial enzyme systems by displacing magnesium ions essential for the enzymatic activity of bacteria ([@b0060]) and subsequently, showing a significant bactericidal effect ([@b0160]).

Several assays have been used to evaluate the inhibitory bacterial growth effect of zinc such as dilution methods and diffusion assays. These methods are considered the most known and fundamental methods to assess the antimicrobial activities of any agent ([@b0015]). Dilution method is used to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC) of the antimicrobial agent. MIC is the lowest concentration that an antimicrobial agent inhibits the growth of the tested organisms whereas MBC is the lowest concentration of any agent killing the majority of bacterial inoculums ([@b0005], [@b0025]). Agar disk-Diffusion method is a well-known method used for routine antimicrobial susceptibility testing, in which diameters of zone of inhibition (ZOI) are measured ([@b0015]).

Although as indicated earlier that many bacterial inhibitory mechanisms of zinc have proposed, and different in vitro assays have shown its clinical value against oral bacteria, however, it seems there is a controversy over the growth inhibitory effectiveness of the zinc against *S. mutans*. Some studies did not find a growth inhibitory effect of zinc against *S. mutans* ([@b0045], [@b0105]) while other studies ([@b0005], [@b0180]) have reported a significant growth inhibitory effect. Hence, a systematic evaluation of the antibacterial effectiveness of zinc is still lacking. Therefore, the aim of this study was to systematically review the growth inhibition effectiveness of zinc against *S. mutans.*

2. Methods {#s0010}
==========

The methods of this review were set according to preferred reporting items for systematic reviews and meta-analyses: The PRISMA statements ([@b0120]). Initially, an addressed question was developed to focus on the main aim of this study. The addressed question was "Does the zinc inhibit the growth of oral *S. mutans* in vitro?"

2.1. Eligibility criteria {#s0015}
-------------------------

The eligibility criteria were: original studies; in vitro studies, studies published in English only. Also studies assessed the antibacterial effectiveness of zinc on *S. mutans* using laboratory methods with reported outcomes either of the following; minimum inhibitory concentration (MIC), minimum bactericidal concentrations (MBC), zone of inhibition (ZOI) and colony forming unit (CFU) were included. Unpublished articles, case reports, short communications and letters to the editor were excluded.

2.2. Information sources {#s0020}
------------------------

Electronic databases (PubMed, Medline, and science direct databases) were searched from 1990 to July 2016 for studies on zinc and its growth inhibition effectiveness against *S. mutans*. It was based on the fact that oral streptococci are the major constituents of dental plaque ([@b0065]), and *S. mutans* is considered the prime bacteria causing dental caries ([@b0110], [@b0145]). Different combinations of keywords were chosen including; zinc; antimicrobial; antibacterial; growth inhibition; mutans streptococci; and *S. mutans*. There was no a priori protocol or a protocol registration. The assessment of the studies included in this review depends on the quality of the studies, their clear results reported and their relevance to this topic. This systematic review developed to summarize the previous and most recent research related to the growth inhibition effectiveness of zinc against *S. mutans*.

2.3. Search strategy and selection of the review studies {#s0025}
--------------------------------------------------------

The full electronic search strategy for all mentioned databases was carried out. Eligibility evaluation of the recourses was undertaken independently by the first two authors. The first author evaluated the titles and abstracts of each study for the eligibility. Then the full articles of the eligible studies were hand searching and screened for additional relevant references. The first author extracted the relevant data from the included studies and checked by the second author. Consensus between the two reviewers was used to resolve any disagreement.

3. Results {#s0030}
==========

3.1. Selection of the studies {#s0035}
-----------------------------

A total of 642 studies were selected from the databases: 61 from Medline Complete, 126 from PubMed and 455 from Science Direct, then reduced to 116 after eliminating duplications and the non-eligible studies by scanning the articles titles and abstracts. There were eighty-nine studies chose and reviewed in full. While, seventy-two articles excluded because of the following reasons:--They were clinical or animal studies.--The required laboratory outcomes of MIC, MBC, ZOI, and CFU were not assessed or not clearly reported.--Used different type of oral bacteria.--Studies tested the antimicrobial effect of zinc that mixed with other materials such as chlorhexidine and fluoride to assess the synergetic effect without testing the zinc alone.--Studies tested/ examined non-silver-containing inorganic antibacterial agents and zinc oxide whisker (ZnOw).

Finally, seventeen studies were included and proceeded for data extraction ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Studies selection.

3.2. Characteristics of the included studies {#s0040}
--------------------------------------------

Seventeen studies met all inclusion criteria in this review. Different *S. mutans* strains were used in these experiments as shown ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Various forms of zinc were reported including zinc sulfate, ([@b0125]), zinc chloride ([@b0030], [@b0040]), zinc citrate ([@b0020]), zinc gluconate ([@b0135]) and zinc oxide ([@b0070], [@b0090], [@b0165]). Zinc in form of Zn-ions that were deposit on titanium (Ti) surface ([@b0180], [@b0190]). Furthermore, zinc oxide nanoparticles were reported the most among recent studies ([@b0005], [@b0045], [@b0055], [@b0060], [@b0075], [@b0140], [@b0185]).Table 1Growth inhibition effectiveness of zinc using MIC and MBC.Study*S. mutans* strainTested zincControl materialP- valueTypeMICMBCTypeMICMBC[@b0040]*S. mutans* GS-5Zinc chloride0.025 mM/l\
(pH 5.5)NAChlorhexidine0.4 µg/ml\
(pH 5.5)NANA0.5 mM/l\
(pH 6)4 mM/l\
(pH 6)0.8 µg/ml\
(pH 6)[@b0030]*S. mutans* IngbrittZinc chloride200 µMNANANANANA[@b0055]*S. mutans*ZnO-NPs500 ± 306.18 µg/ml500 µg/mlNANANANA[@b0135]NCTC 10449Zinc gluconate2.8 mM11 mMNANANANA[@b0045]*S. mutans* 700610 (clinical isolate)ZnO-NPsNo growth inhibitionNANANANANA[@b0005]PTC 1683ZnO-NPs0.390 µg/ml3.125 µg/ml0.2% Chlorhexidine62.5 µg/ml83.33 µg/mlP \< 0.001[@b0185]ATCC 25175ZnO-NPs0.156 mg/ml0.312 mg/mlNANANA[^1]Table 2Growth inhibition effectiveness of zinc using ZOI.Study*S. mutans* strainTested zincNegative controlP- valueTypeMean ZOITypeMean ZOI[@b0125]ATCC 251755% and 10% zinc sulfate (ZnSO4) added to conventional glass Ionomer cement (GIC) and Resin Modified Glass Ionomer Cement (RMGIC).After 1 hr10 wt% provides ZOI of 2.2 mmConventional glass Ionomer cement (GIC) and Resin Modified Glass Ionomer Cement (RMGIC) 0% zinc\< 1.5NAAfter 15 daysNo inhibition zoneGIC &RMGIC with 0% zinc0  [@b0165]NA13% ZnO or 23.1% ZnO was added to orthodontic bonding material (Ortho Fuji LC) a resin-modified glass ionomer (RMGI)After 48 hrs•13% provides ZOI of 70.52 ± 17.33 mm^2^ equivalent to 9.4 mm•23.1% provides ZOI of 110.03 ± 31.00 mm^2^ equivalent to 11.83 mmOrthodontic bonding (Ortho Fuji LC) a resin-modified glassionomer (RMGI) 0% ZnO0P \< 0.00After 1 month•13% provides ZOI of 16.0 ± 11.6 mm^2^ equivalent to 4.5 ± 3.7 mm•23.1% provides ZOI of 38.3 ± 13.3 mm^2^ equivalent to 6.95 ± 4.0 mmOrthodontic bonding (Ortho Fuji LC) a resin-modified glass ionomer (RMGI) 0% ZnO0P \< 0.00  [@b0060]PTCC 1683Five resin composites containing 1, 2, 3, 4, 5 wt% ZnO-NPsNo inhibition zoneResin composite without ZnO-NPs0NA  [@b0070]NA13% and 23.1% ZnO was added to a resin modified light cure glass ionomer cement (RMGIC).After 48 hrs•13% provides ZOI of 12.50 ± 0.707 mm•23.1% provides ZOI of 21 ± 1.4 mmConventional light cure composite without zinc and RMGIC without zinc0P \< 0.01After month•13% provides ZOI of 10 ± 0.00 mm•23.1% provides ZOI of 19 ± 0.00 mmConventional light cure composite without zinc and RMGIC without zinc0P \< 0.01[^2]Table 3Growth inhibition effectiveness of zinc using CFU.Study*S. mutans* strainTested zincControl materialP- valueTypeNumber/mean CFUTypeNumber/mean CFU[@b0020]*S. mutans* R9Zinc citrate solution (39.8 µmol/l)Log~10~ CFU/ml post dosing of zinc citrate after 24 hrs was 4.08 and after 48 hrs was 4.36Pre-dosing of zinc citrateLog~10~ CFU/ml ± SD) was 4.75 ± 0.42P **\> 0.05**  [@b0180]UA159Zn-ion were deposit on titanium (Ti) surface by time of 20 min intervals:\
Zn--Ti-20, Zn--Ti-40, Zn--Ti-60 and Zn--Ti-80Zn--Ti-200.8 ± 0.2cp-Ti without Zn2.6 ± 0.3P \< 0.01Zn--Ti-400.6 ± 0.3Zn--Ti-600.2 ± 0.1Zn--Ti-800.1 ± 0.0CFU (×10^9^ mL)  [@b0060]PTCC 1683Resin composites containing 0--5 wt% ZnO-NPs4 and 5 wt% groups entirely inhibit formation of any bacterial colony.Resin composites with no zinc additive.CFU of 160,000P \< 0.05CFU after 48 hrs was 20,000 and lessCFU after 48 hrs was 80,000P \< 0.05No significant difference between the test and control groups after 1 week or 1 monthP \> 0.05[@b0190]ATCC 25175Micro-arc oxidation (MAO) coatings for titanium coated with different concentrations of zinc ions in electrolyteMean CFU of:-\
High Zn 0.05 mol/l was 15.25 ± 2.13\
Medium Zn 0.03 mol/l was 22.10 ± 2.21\
Low-Zn 0.01 mol/l was 27.45 ± 3.23No-Zn Titanium coatingsCFU was 73.28 ± 3.67.P \< 0.05  [@b0075]PTCC 1683Composite resins containing 1% ZnO-NPsMean CFU was 0.93 ± 1.53Composite resin without zincMean CFU was 126.0 ± 29.47P = 0.00  [@b0090]UA 1590.01 g and 0.05 g Calcium phosphate glass doped with ZnOCFU/ml of 0.01 g after 2 hrs was 3.68 × 10^4^.\
\
Calcium phosphate glass (0.01 g CPG) without zinc dopingAfter 4 hrs CPG 0.01 g had CFU/ml of 5.48 × 10^4^/ml**NA**At 4 hrs showed 100% bactericidal activity continued for 6 hrs.0.05 g produced a maximum bactericidal effect at 2 hrs compared to 4 hrs with 0.01 g.0.05 g CPG without zinc doping0.05 g CPG showed maximum bactericidal effect at 4 hrsA negative control with no (CPG)CFU/ml was 1.31 × 10^7^  [@b0140]ATCC 35668ZnO-NPs coated bracketsMean CFU after\
0 hr 140.84 ± 65.79\
2 hrs 96.78 ± 46.19\
4 hrs 96.10 ± 75.64Uncoated bracketsMean CFU after\
0 hr 165.91 ± 53.19\
2 hrs 139.33 ± 43.71\
4 hrs 135.08 ± 68.93P = 0.844\
6 hrs 55.89 ± 51.95\
24 hrs 219.32 ± 304.53\
6 hrs 117.75 ± 66.68\
24 hrs 921.25 ± 823.68\
P \< 0.001  Ahrari et al. (2015)PTC 1683Colloidal solutions containing ZnO-NPsMean CFU after 1 min was 2900 ± 655\
Mean CFU after 5 min was 1153 ± 799Chlorhexidine (positive control)Mean CFU after 1 min and 5 min was 0P \< 0.001Sodium fluoride mouthrinses (negative control)Mean CFU after 1 min and 5 min was 4666 ± 577P \< 0.001[^3]

Studies have reported different ways of zinc ion introduction. Some studies used aqueous solutions to introduce the zinc ion (Zn^2+^). ([@b0005], [@b0020], [@b0030], [@b0040], [@b0045], [@b0055], [@b0135]). Other studies incorporated Zn^2+^ into the structure of some dental materials to investigate it's the antimicrobial effectiveness ([@b0060], [@b0070], [@b0075], [@b0090], [@b0125], [@b0140], [@b0165], [@b0180], [@b0185], [@b0190]). In this review, two studies have reported more than one antibacterial method to assess the antibacterial effectiveness of zinc against *S. mutans*. [@b0060] had reported the evaluation by ZOI and CFU where [@b0005] reported using MIC, MBC, and CFU.

Overall, seven studies reported MIC and MBC ([@b0005], [@b0030], [@b0040], [@b0045], [@b0055], [@b0135], [@b0185]). Four studies have reported ZOI using agar diffusion method ([@b0060], [@b0070], [@b0125], [@b0165]). Additionally, eight studies reported zinc antibacterial inhibition efficacy through viable CFU ([@b0005], [@b0020], [@b0060], [@b0075], [@b0090], [@b0140], [@b0180], [@b0190]). Using these outcomes, only two studies out of seventeen indicated no growth inhibition efficacy of the zinc against *S. mutans* ([@b0020], [@b0045]).

3.3. Growth inhibition of zinc against S. Mutans {#s0045}
------------------------------------------------

### 3.3.1. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) {#s0050}

The results of the MIC and MBC evaluation indicated that zinc acts effectively against *S. mutans*. These studies were used different forms of zinc either as salts (zinc chloride, zinc gluconate) or as ZnO-NPs. Generally, low MIC and MBC values of zinc were stated. MIC values using zinc chloride were ranged from 0.025 mM to 0.2 mM. The MIC using ZnO-NPs have ranged from 0.390 to 500 ± 306.18 µg/ml. The MBC using ZnO-NPs ranged from 3.125 to 500 µg/ml. However, a study done by [@b0045] using ZnO-NPs did not report any growth inhibition of *S. mutans* even after increasing the concentrations of ZnO-NPs to 1.0 mg/ml ([Table 1](#t0005){ref-type="table"}).

### 3.3.2. Zone of inhibition (ZOI) {#s0055}

[Table 2](#t0010){ref-type="table"} provides a summarized data regarding the ZOI using agar diffusion method. In general, limited studies are using this method. In this review, all studies reported inhibition zone in millimeters expect one study which reported inhibition zone in squared millimeters^2^, where the equivalent mm was calculated. All of the reviewed studies were testing the antibacterial of zinc added to orthodontic bonding agents or a resin cement. The negative controls were the same tested materials but without adding zinc. The use of zinc resulted in either no inhibition zone to a moderate inhibition zone. The inhibition zone for zinc ranged from no inhibition zone using ZnO-NPs ([@b0060]) to 21 ± 1.4 mm using 23.1% ZnO ([@b0070]). Studies have shown that the antibacterial activity of zinc increased as the concentration of zinc increased ([@b0070], [@b0165]). Therefore, 23.1% of ZnO exhibited a greater ZOI than 13% ZnO. Additionally, it appears that fresh mixed zinc showed more antibacterial properties compared to old zinc mixture ([@b0070], [@b0125], [@b0165]).

### 3.3.3. Colony Forming Unit (CFU) {#s0060}

[Table 3](#t0015){ref-type="table"} shows the viable bacteria counts of dental materials treated with zinc as compared to the negative control (no zinc added). Only one study did not find a significant inhibition of the viable count of *S. mutans* even after 48 hrs of using zinc citrate ([@b0020]). However, all the other studies demonstrated that zinc significantly reduced the viability of *S. mutans* compared to the controls ([@b0005], [@b0060], [@b0075], [@b0090], [@b0140], [@b0180], [@b0190]). The reviewed studies have agreed that antibacterial effectiveness of zinc was concentration-dependent. With an increase in the concentration of zinc, there was an increase in the antibacterial effectiveness ([@b0060], [@b0140], [@b0180], [@b0190]). In the study by [@b0060] both agar diffusion method and direct contact test were done to assess the zinc effectiveness against *S. mutans*. Even though no inhibition effect was reported using agar diffusion test, however, direct contact test has demonstrated greater *S. mutans* viability inhibition when zinc added to resin composite that persisted for more than 48 h. As mentioned earlier, fresh mixed zinc exhibited higher antibacterial properties than aging material. However, after one week there was no significant difference between either of the test and control groups (P \> 0.05) ([@b0060]).

4. Discussion {#s0065}
=============

This study aimed to review growth inhibitory effect of zinc against *S. mutans* and to gain further and specific conclusions about the antibacterial activity of different zinc forms.

This review has indicated that although several zinc antimicrobial inhibitory mechanisms have been proposed ([@b0130]). However, we still found some laboratory studies did not support this finding ([@b0020], [@b0045]).

Zinc is an environmentally friendly material and has little toxicity ([@b0010]). It is naturally present in dental plaque and saliva ([@b0100]). Due to its antibacterial properties, zinc effectively and commonly used for dermatological applications in creams, lotions and ointments ([@b0010]). Additionally, it has been used widely in dentistry; it incorporated in dental materials and in oral health products including toothpaste and mouth rinse without the concern of high toxicity or unfavorable side effects, where its higher concentration can persist for many hours after delivery from oral health products ([@b0100]).

In this review, we included studies that used zinc as antibacterial against *S. mutans* with outcomes of MIC, MBC, the ZOI and viable bacterial count method using CFU. These methods were selected as they are considered the most known assays to evaluate the antimicrobial activity of any agent ([@b0015]).

Overall, the majority of the studies have reported antibacterial properties of zinc either in the form of powder salts or nanoparticles form against *S. mutans*, even at very lower concentrations ([@b0005], [@b0030], [@b0040], [@b0055], [@b0060], [@b0070], [@b0075], [@b0090], [@b0125], [@b0135], [@b0140], [@b0165], [@b0180], [@b0185], [@b0190]). Though, only two studies did not report such a finding ([@b0020], [@b0045]). The first study by [@b0020] that did not reported any antibacterial properties of zinc against *S. mutans*. It has indicated that using complex media components might render the tested zinc citrate ineffective. The other study by [@b0045] did not report any MIC of ZnO-NPs against *S. mutans* even after increasing the concentrations of ZnO-NPs to 1.0 mg/ml. Although the other studies included in this review have shown even lower MIC concentrations using ZnO-NPs, thus, most likely this variation is attributed to differences in the strains of the bacteria that utilized in each study, where in the study by [@b0045] has used clinical isolate *S. mutans* strain. Additionally, in this review we found that fresh mixed zinc exhibited higher antibacterial properties than aging material, possibly due to increasing the release of Zn^2+^ from the fresh mixture and this effect tends to be less with time ([@b0060], [@b0070], [@b0125], [@b0165]).

A considerable body of literature has indicated that ZnO-NPs exhibits significant antibacterial activity over a broad spectrum of bacterial species ([@b0160]). In the early stage of this review, we planned to include only the powder form of zinc instead of nanoparticles. However, due to the limited number of studies, ZnO-NPs studies were included. Adequate number of the studies included in this review have tested the antibacterial effectiveness of zinc in form of nanoparticles mainly ZnO-NPs ([@b0005], [@b0045], [@b0055], [@b0060], [@b0075], [@b0140], [@b0185]). Almost all of these studies have shown promising results indicated significant antibacterial inhibition effect and safety applications.

One of the proposed antimicrobial mechanism of ZnO-NPs could be due to the leaching of Zn^2+^ into the growth media, and the interference of Zn^2+^ ions with the enzyme systems of the bacteria by displacing with magnesium ions which is crucial for bacterial enzymatic activities ([@b0060]). The agar diffusion test is one of the most popular used methods to determine the antimicrobial activity of an agent ([@b0015]). Agar diffusion test can be considered for materials which are soluble and capable of diffusing into the surrounding environment ([@b0175]). That may explain why the study by [@b0060] using ZnO-NPs did not reveal any ZOI using agar diffusion method. The insolubility of the ZnO-NPs hindered diffusion of an adequate amount of Zn^2+^ to the surrounding environment to show a visible antibacterial effect ([@b0150]).

Despite the significant antibacterial activity of zinc, one of the limiting factors in the use of zinc as nanoparticles is due to the different effective antibacterial concentration against *S. mutans*, toxicological impact and potentially undesirable effects on the human body. Minimal concentration might not be effective against the *S. mutans*, and higher concentration could possibly induce cytotoxicity and genotoxicity. The presence of ZnO-NPs in dental care products such as toothpaste and mouthwash implicates a major source of exposure since people use these products 2--3 times daily. Therefore, much attention is paid to the question of whether ZnO NPs in these products are able to cross the oral mucosa barrier and results in inflammation and systemic toxicity via dermal penetration ([@b0115]). Another possible route of entry is via the oral route ([@b0155]). Even though the dental care products are not directly ingested, but there is still a risk of ingestion during the use.

Toxicity of ZnO-NPs was reported in vitro studies at different concentrations. However, it has been noticed that most of the data reported the toxicity below 100 μg/mL for a normal cell. As reported by [@b0115], 85% reduction in cell viability was observed upon treatment of human dermal fibroblast with ZnO-NPs at concentrations ranging from 25 to 100 μg/ml and at concentration 50 μg/ml the ZnO-NPs had induced the cell apoptosis. A significant increase in DNA damage in human nasal mucosa was also observed upon repetitive (2--3 times) and short exposure (1 hr per exposure) to 5 μg/ml of ZnO-NPs ([@b0050]). ZnO-NPs also showed cytotoxic activity by acting on different targets in renal cells, with IC~50~ ≥ 73.05 μg/ml ([@b0170]).

The nanoparticles when ingested into the body can be distributed to different regions because of their small size. Even though zinc is an essential trace element in the human body and ZnO is generally considered to be a compound with low toxicity, but the nanoparticle form is more reactive and responsive with higher absorptivity. Biodistribution or accumulation on ZnO-NPs was reported in many organs depending on route of administration. For experiment, treatment via the oral administration on mice (fed treatment), ZnO-NPs (2.5 g/kg) were reported to enter into blood circulation within 30 min post-dosing, and clearance in serum began 6 hrs after administration ([@b0085]). [@b0155] reported significant accumulation of nanoparticles in the mouse liver leading to cellular injury after sub-acute oral exposure of ZnO-NPs (300 mg/kg) for 14 consecutive days. In addition, the levels of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the treated group were higher compared to the control group and the histopathology examination of liver and kidney showed pathological lesions.

In spite of many advantages in using nanotechnology, several studies indicate that nanoparticles may cause hazardous effects because of their unique physicochemical properties ([@b0170]). The obtained toxicological data so far for ZnO-NPs are also conflicting and inconsistent. The reported doses do not directly reflect the actual concentrations of ZnO-NPs that could induce toxicity in human because no human study or clinical trial was reported. However, the toxicological data derived from in vitro and in vivo studies can be used to assess the possible human health risks from exposure to ZnO-NPs.

Lastly, although the focus of this review was on a single bacterial approach which is *S. mutans,* the prevailing cariogenic bacteria involving in initiation and progression of dental caries ([@b0110], [@b0145]) and in vitro studies, the collected findings allowed to definitely assess the effectiveness of zinc against *S. mutans.* However, certain limitations in the present study should be highlighted. First, neither definitive conclusions about wider range of bacteria nor the antibacterial efficacy of zinc in the clinical studies can be made from this review, as in vitro studies and one type of bacteria were included. Second, language bias which might be present because we included only papers published in English.

5. Conclusions {#s0070}
==============

In the light of the above facts, zinc is an effective antibacterial agent against the growth of *S. mutans* bacteria even at lower concentrations. Its effectiveness is dependent on the zinc concentrations and type. Therefore, we concluded that zinc in different forms is an antibacterial agent, potentially can be considered for developing further valuable oral health care products and to be added to dental materials. Additionally, with the evolution of nanotechnology and use of ZnO-NPs, promising steps toward more effective therapeutic approaches can be developed to enhance the antibacterial properties of zinc in future.
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[^1]: MIC; minimum inhibitory concentration, MBC; minimum bactericidal concentration, ATCC; American Type Culture Collection, ZnO-NPs; Zinc Oxide Nanoparticles.

[^2]: ZOI; Zone of Inhibition, ZnO; Zinc oxide, ZnO-NPs; Zinc Oxide nanoparticles, NA; Not available.

[^3]: CFU; Colony Forming Unit, min; minute, cp-Ti; Commercial Titanium, ZnO; Zinc Oxide, ZnO-NPs; Zinc Oxide nanoparticles, CPG; calcium phosphate glass, hrs; hours, NA; Not available.
